4ypg: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Structural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal Antibody== | ==Structural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal Antibody== | ||
<StructureSection load='4ypg' size='340' side='right' caption='[[4ypg]], [[Resolution|resolution]] 3.00Å' scene=''> | <StructureSection load='4ypg' size='340' side='right' caption='[[4ypg]], [[Resolution|resolution]] 3.00Å' scene=''> | ||
| Line 4: | Line 5: | ||
<table><tr><td colspan='2'>[[4ypg]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YPG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4YPG FirstGlance]. <br> | <table><tr><td colspan='2'>[[4ypg]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YPG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4YPG FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ypg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ypg OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ypg RCSB], [http://www.ebi.ac.uk/pdbsum/4ypg PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ypg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ypg OCA], [http://pdbe.org/4ypg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4ypg RCSB], [http://www.ebi.ac.uk/pdbsum/4ypg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4ypg ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 16: | Line 17: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 4ypg" style="background-color:#fffaf0;"></div> | |||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 17:23, 29 March 2017
Structural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal AntibodyStructural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal Antibody
Structural highlights
Function[IFNA2_HUMAN] Produced by macrophages, IFN-alpha have antiviral activities. Publication Abstract from PubMedWe report the three-dimensional structure of human interferon alpha-2A (IFN-alpha2A) bound to the Fab fragment of a therapeutic monoclonal antibody (sifalimumab; IgG1/k). The structure of the corresponding complex was solved at a resolution of 3.0 A using molecular replacement and constitutes the first reported structure of a human type I IFN bound to a therapeutic antibody. This study revealed the major contribution made by the first complementarity determining region (CDR) in each of sifalimumab light and heavy chains. These data also provided the molecular basis for sifalimumab mechanism of action. We propose that its interferon-neutralizing properties are the results of direct competition for IFN-alpha2A binding to the IFN receptor subunit 1 (IFNAR1) and do not involve inhibiting IFN-alpha2A binding to the IFN receptor subunit 2 (IFNAR2). Structural Insights Into the Neutralization Properties of the Fully Human, Anti-Interferon Monoclonal Antibody Sifalimumab.,Oganesyan V, Peng L, Woods RM, Wu H, Dall'Acqua WF J Biol Chem. 2015 Apr 29. pii: jbc.M115.652156. PMID:25925951[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||